Why the study?
Does perioperative combination of COX2 and beta-adrenergic blockade improve outcomes in patients with resectable colorectal cancer?
Does perioperative combination of COX2 and beta-adrenergic blockade improve outcomes in patients with resectable colorectal cancer?
Answers are grounded in this paper and cite their sources.
This editorial discusses a randomized trial evaluating repurposed drugs (COX2 and beta-blockers) to prevent cancer metastases after surgery.
Despite dramatic improvements in survival for most cancers over the past decade, outcomes for cancer patients with metastatic disease continue to be dismal. Haldar et al present a randomized trial of the perioperative combination of COX2 and beta‐adrenergic blockade in patients with resectable colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Lowe et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: